- In March 2024, Bruker Corporation announced significant progress in immunopeptidomics, glycoproteomics, and other advanced 4D proteomics workflows. These developments underscore Bruker's commitment to providing cutting-edge solutions for deep, at-scale proteomics, glycomics, and peptidomics research, enabling critical insights into disease biology and biomarker discovery
- In January 2024, Vector Laboratories, a prominent provider of proteomic and glycomic research solutions, and Navinci Diagnostics, a leader in in situ proximity ligation assay-based solutions, signed an agreement. This collaboration aims to create cutting-edge biomarker discovery techniques that will identify specific protein glycosylation in tissue samples for the first time, advancing personalized medicine
- In February 2024, Asparia Glycomics launched CarboQuant, a cutting-edge glycan analysis technology designed for absolute glycan quantification with unparalleled precision. This proprietary technology leverages synthetic ¹³C-labeled N-glycans and mass spectrometry to enable researchers to uncover glycan biomarkers linked to diseases such as cancer, Alzheimer's, and diabetes
- In June 2023, Agilent Technologies Inc. introduced the Agilent BioTek 406 FX washer dispenser, a compact instrument offering versatile reagent dispensing and plate-washing capabilities. Designed for integration in automated systems or for standalone benchtop use, the BioTek 406 FX enhances liquid handling functions
- In December 2023, Griffith University's Institute for Glycomics received significant funding for its research programs, including those focused on targeting sugar structures to fight bacterial infections and unraveling malaria invasion mechanisms. Such funding highlights the increasing global recognition and investment in glycomics research for developing new drugs and vaccines
